NIH Data Shows Improvement in Clinical Trial Results Reporting, but Deadlines Still Missed
Key Insights
NIH data reveals that 41% of clinical trial results were submitted to ClinicalTrials.gov in fiscal year 2022, marking an increase from previous years.
While the vast majority (96%) of trial results are eventually submitted, most are late, with only about one-third submitted by the required due dates.
A recently enacted NIH policy aimed at improving trial results reporting appears to be effective, but further action is needed to enhance timely compliance.
The National Institutes of Health (NIH) has released data indicating a positive trend in the reporting of clinical trial results, although adherence to deadlines remains a challenge. The data, posted in response to growing criticism, shows that in fiscal year 2022, 41% of trial results were submitted to the ClinicalTrials.gov federal database. This represents an increase from 34% in the previous year and 29% in fiscal year 2020.
Reporting Rates and Timeliness
While the submission rate has improved, the data also reveals that most trial results are submitted late. On average, 96% of results were eventually submitted to the database, but only slightly over one-third were submitted by the obligatory due dates. This highlights a persistent issue with timely reporting despite the overall increase in submissions.
NIH Policy and Enforcement
Mike Lauer, the deputy director for extramural research at the NIH, addressed the findings in a March 24 blog post, suggesting that a recently implemented agency policy designed to enhance the reporting of trial results is showing promise. However, Lauer acknowledged that the NIH still has "work to do to increase timely compliance" and indicated that enforcement actions will be taken against non-compliant trial sponsors "if needed."
The NIH's commitment to enforcing compliance underscores the importance of timely and accurate reporting of clinical trial results for transparency and the advancement of medical knowledge.